You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

Abbott Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for ABBOTT, and what generic and branded alternatives to ABBOTT drugs are available?

ABBOTT has one hundred and eleven approved drugs.

Summary for Abbott

US Patents:	0
Tradenames:	89
Ingredients:	62
NDAs:	111

Drugs and US Patents for Abbott

+ Get email alerts for changes to this table

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbott	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER	sodium chloride	SOLUTION;INJECTION	019218-002	Apr 30, 1985		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Abbott	AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER	amino acids; calcium chloride; dextrose; magnesium chloride; potassium chloride; potassium phosphate, dibasic; sodium chloride	INJECTABLE;INJECTION	019714-002	Sep 12, 1988		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Abbott	A-POXIDE	chlordiazepoxide hydrochloride	CAPSULE;ORAL	085517-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Abbott	JANIMINE	imipramine hydrochloride	TABLET;ORAL	017895-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Abbott	AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER	amino acids; dextrose	INJECTABLE;INJECTION	019118-001	Oct 11, 1984		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
Abbott	DEPAKOTE CP	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	019794-001	Jul 11, 1990		DISCN	No	No		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Abbott

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-003	Aug 7, 1987	5,294,615	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-002	Aug 7, 1987	5,212,176	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-003	Dec 14, 1994	5,212,176	⤷ Sign Up
Abbott	DEPAKOTE CP	divalproex sodium	TABLET, DELAYED RELEASE;ORAL	019794-001	Jul 11, 1990	4,988,731*PED	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	CAPSULE;ORAL	020347-004	Dec 14, 1994	5,504,207	⤷ Sign Up
Abbott	HYTRIN	terazosin hydrochloride	TABLET;ORAL	019057-001	Aug 7, 1987	5,294,615	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBOTT drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Capsules	10 mg and 15 mg	➤ Subscribe	2009-08-14
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.